Morepen Laboratories (NSE:MOREPENLAB) Other Current Liabilities: ₹1,031 Mil (As of Mar. 2026)


NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
75 GF Score
Price ₹59.79
GF Value ₹49.87
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Morepen Laboratories Other Current Liabilities?

Morepen Laboratories NSE:MOREPENLAB -4.61% 75 Other Current Liabilities is ₹1,031 Mil as of Mar. 2026. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 75/100 and a GF Value™ of ₹49.87 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Morepen Laboratories's other current liabilities for the quarter that ended in Mar. 2026 was ₹1,031 Mil.

Morepen Laboratories's quarterly other current liabilities declined from Sep. 2025 (₹890 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹1,031 Mil).

Morepen Laboratories's annual other current liabilities declined from Mar. 2024 (₹579 Mil) to Mar. 2025 (₹577 Mil) but then increased from Mar. 2025 (₹577 Mil) to Mar. 2026 (₹1,031 Mil).

Morepen Laboratories Other Current Liabilities Related Terms

Morepen Laboratories Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Morepen Laboratories Other Current Liabilities Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,760.29 462.62 579.40 577.45 1,030.70

Morepen Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 577.45 0.00 889.80 0.00 1,030.70
NSE:MOREPENLAB
75GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Morepen Laboratories Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹1,031 Mil mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Other Current Liabilities of ₹1,031 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Morepen Laboratories.
Is Morepen Laboratories' Other Current Liabilities too high?
Morepen Laboratories' current Other Current Liabilities is ₹1,031 Mil. Overall, Morepen Laboratories has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Other Current Liabilities compare to ZTS and UTHR?
Morepen Laboratories' Other Current Liabilities of ₹1,031 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Morepen Laboratories. Morepen Laboratories's current Other Current Liabilities is ₹1,031 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹49.87, compared to a current price of ₹59.79 — trading 19.9% above its estimated fair value. The current Other Current Liabilities is ₹1,031 Mil. Morepen Laboratories' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Other Current Liabilities is ₹1,031 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹59.79 is trading 19.9% above its estimated GF Value™ of ₹49.87. GuruFocus considers Morepen Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:MOREPENLAB:

  • Other Current Liabilities: ₹1,031 Mil
  • GF Value™: ₹49.87 vs. price of ₹59.79 (19.9% above fair value)
  • GF Score™: 75/100 with 6 warning signs

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
75GF Score

Get the complete analysis for NSE:MOREPENLAB

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹59.79
Price
₹49.87
GF Value